Should I buy UiPath (PATH) stock or is it too late?

UiPath · Information Technology · price $13

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: RBC Capital — 64% of its targets hit on this sector (141 calls tested). It aims for $15 (+13 %), call made on September 24, 2026, maturing on September 24, 2027 (20 d ago).

The 5 reliable analysts $15+13 %

The 9 other firms $15+13 %

How to read it: the 5 reliable firms are not filtered by optimism — 4 aim above the price, 1 below, hence their $15 median. “The 9 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on UiPath

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Wells Fargo	50 %	+4.5 %	8	$15 +13%
Canaccord Genuity	43 %	-15.7 %	7	$14 +6%
Truist Securities	43 %	-16.3 %	7	$14 +6%
Needham	30 %	-20.8 %	10	$22 +66%
Credit Suisse	57 %	+5.2 %	7	—

In short — Should you invest in UiPath? Is it too late, still worth it? Analysts are split (14% buy, median target $15, i.e. +13%), and the most reliable on PATH targets even higher. But the stock is volatile, it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Median price target $15, i.e. +13% from the current price ($13).
The most reliable firm on PATH, Wells Fargo (50% hit rate, 8 scored calls), targets $15 (call made on September 4, 2026, maturing on September 4, 2027) (+13%) in its most recent call, and $13 (call made on March 12, 2026, maturing on March 12, 2027) (-2%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 14 ratings, 10 are neutral and 2 are sells.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
Volatile stock: sharp swings — including steep drops — are part of its profile.
No dividend: your return depends only on price appreciation.

The analyst consensus on PATH

Median target $15 (+13%) · 14 ratings · Hold consensus

Strong Buy00%

Buy214%

Hold1071%

Sell214%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in UiPath now?

We won't decide for you. The facts: 14% of analysts rate it a buy, median target $15 (+13%), and Wells Fargo (most reliable on PATH, 50%) targets $15. Weigh that against valuation and volatility. This is not personalized advice.

Is it too late to invest in UiPath?

Not according to analysts: the median target ($15) is still +13% above the current price ($13) (most reliable on PATH: Wells Fargo, 50%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is UiPath still worth investing in?

It depends on the gap between the price ($13) and its estimated value: analysts target $15 on median (+13%), with 14% buys (most reliable on PATH: Wells Fargo, 50%). Cross-check with their real reliability on PATH and the cautions above. Information, not advice.

What's the main risk in buying PATH?

The consensus is not unanimous: of 14 ratings, 10 are neutral and 2 are sells.

→ Go deeper: the full UiPath profile (consensus, analyst reliability, price target, performance).